Recro Pharma Inc (NASDAQ:REPH) was the recipient of a significant growth in short interest in November. As of November 29th, there was short interest totalling 1,260,000 shares, a growth of 17.8% from the November 14th total of 1,070,000 shares. Based on an average daily volume of 269,500 shares, the short-interest ratio is currently 4.7 days. Approximately 6.5% of the company’s stock are short sold.
REPH traded up $0.06 on Friday, reaching $16.81. 354,870 shares of the company traded hands, compared to its average volume of 299,062. The stock’s 50 day moving average price is $16.02 and its 200-day moving average price is $12.03. Recro Pharma has a 52-week low of $5.53 and a 52-week high of $18.20.
Recro Pharma (NASDAQ:REPH) last posted its earnings results on Friday, November 8th. The specialty pharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.13) by ($0.06). The business had revenue of $25.26 million for the quarter, compared to analysts’ expectations of $19.83 million. On average, equities analysts forecast that Recro Pharma will post -0.6 earnings per share for the current fiscal year.
A number of research analysts recently commented on the stock. ValuEngine downgraded shares of Recro Pharma from a “buy” rating to a “hold” rating in a research report on Tuesday, December 3rd. Stephens lowered their price objective on shares of Recro Pharma from $23.00 to $19.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 26th. BidaskClub raised shares of Recro Pharma from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, October 22nd. Finally, Zacks Investment Research raised shares of Recro Pharma from a “hold” rating to a “buy” rating and set a $15.00 price objective on the stock in a research report on Wednesday, October 30th. Two research analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of “Buy” and an average target price of $14.90.
About Recro Pharma
Recro Pharma, Inc, a specialty pharmaceutical company, develops and commercializes products for hospital and related acute care settings. The company operates in two segments, Acute Care, and Contract Development and Manufacturing. Its lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain.
Read More: Blue-Chip Stocks
Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.